Clinical Trial Update: Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating aldesleukin with or without ziv-aflibercept in patients with unresectable stage III-IV metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• Ziv-aflibercept (ziv-aflibercept)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Melanoma, Recurrent Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2019-05-10